Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Benzinga

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

This clinical-stage biotech stock has a strong pipeline capable of creating the next Moderna.

Barchart

FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Robert F. Kennedy Jr. Just Did The Unexpected. He Helped Moderna.

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Investors Business Daily

Did Down-And-Out Moderna Just Unlock The Key To Its Future Profitability?

Moderna stock veered higher Monday after its flu shot proved to be as effective as older technology in a final-phase study.

Investors Business Daily

RFK Jr.'s made promises about vaccines. Here's what he's done as health secretary

The Department of Health and Human Services under Robert F

The Independent UK

COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know

FDA has updated safety warnings for the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group

Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts and former federal officials after its first meeting strayed sharply from established scientific review norms.

Benzinga

US experts fear all vaccines at risk as Trump officials target mRNA jabs

Administration’s actions signal move away from technology as health agencies see vaccine-related shakeups

The Guardian - US

Vaccine Stocks Mixed After RFK Jr. Fires CDC's Entire Vaccine Committee

Vaccines stocks were mixed Tuesday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.

Investors Business Daily

How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks?

Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.

Barchart

What you need to know about Moderna's new COVID vaccine, just approved by the FDA

The shot had previously been approved for everyone 12 and older. Now, there are limits.

Fortune

FDA approves Moderna's new lower-dose COVID-19 vaccine

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it

The Independent UK

HHS cancels funding for bird flu vaccine development because of RNA concerns

The Trump administration said the move signals a ‘shift in federal vaccine funding priorities’

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

Moderna Loses $700M US Contract for Bird Flu Vaccine Development

Moderna loses $700 million U.S. contract to develop bird flu vaccine after government review ends funding.

The Independent UK

Trump administration cancels $766 million Moderna contract to fight pandemic flu

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including H5N1 bird flu

The Independent UK

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter

MarketBeat

Moderna Stock Looks Ripe for a Short Squeeze

Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Moderna Wipes Out Its Recent Rally As It Faces Another Vaccine Setback

Moderna stock toppled Wednesday after the company withdrew its application for a combination Covid and flu vaccine.

Investors Business Daily

The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.

The FDA said Tuesday it will limit future Covid vaccines to older and at-risk Americans. The move buoyed Moderna, BioNTech and Novavax.

Barchart

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna is the largest market cap in Barchart’s Bottom 100 Stocks to Buy. On Monday, the vaccine maker moved seven spots to the 86th position. You don’t want to make this list if you are the CEO. Here’s why.

Fortune

This Moderna leader uses AI to resolve conflict on the executive team—all before it even happens

“I think I’m pretty good with people, but it gives me an advantage that I didn’t have before.”

LiveScience

2-in-1 COVID-flu vaccine looks promising in trial — but experts say approval may be delayed

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.

Investors Business Daily

Analysts Say 9 Stocks Will Pay Off If You 'Buy The Dip'

Savvy investors know that buying leading growth stocks is the best way to profit long term. But there's a rush to buy the dip in the S&P 500.

Barchart

Moderna Stock: Analyst Estimates & Ratings

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

the Food and Drug Administration

181 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.